Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial
Abstract
Autologous stem cell therapy in the field of regenerative veterinary medicine involves harvesting tissue, such as fat, from the patient, isolating the stem and regenerative cells, and administering the cells back to the patient. Autologous adipose-derived stem cell therapy has been commercially available since 2003, and the current study evaluated such therapy in dogs with chronic osteoarthritis of the hip. Dogs treated with adipose-derived stem cell therapy had significantly improved scores for lameness and the compiled scores for lameness, pain, and range of motion compared with control dogs. This is the first randomized, blinded, placebo-controlled clinical trial reporting on the effectiveness of stem cell therapy in dogs.
Chief Executive Officer at Gallant
Dr. Linda Black, DVM, PhD, is Chief Executive Officer of Gallant and a founding member of the company, previously serving as President and Chief Scientific Officer. She brings extensive leadership experience across biotechnology, spanning corporate development, research and development, operations, and commercialization, with deep expertise in regenerative medicine and stem cell therapies for pets.
Prior to Gallant, she served as President and Chief Scientific Officer of Medicus Biosciences and as Vice President of Product Development at VetStem Biopharma, where she helped pioneer the first off-the-shelf stem cell therapies for dogs. Dr. Black has authored foundational research on adipose-derived stem cells and has led programs advancing these therapies to commercialization. She holds a DVM from the University of Wisconsin–Madison and a PhD in Cell and Molecular Biology from the University of Pennsylvania.
